ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVC ABVC BioPharma, Inc.

Market Closed 12-12 16:00:00 EST

2.11

-0.14

-6.22%

盘后2.11

+0.000.00%

16:10 EST

High2.26	Low2.09	Vol110.48K
Open2.25	D1 Closing2.25	Amplitude7.78%
Mkt Cap51.28M	Tradable Cap45.45M	Total Shares24.30M
T/O238.81K	T/O Rate0.51%	Tradable Shares21.54M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":2.11,"timestamp":1765573200000,"preClose":2.25,"halted":0,"volume":110481,"hourTrading":{"tag":"盘后","latestPrice":2.11,"preClose":2.11,"latestTime":"16:10 EST","volume":53,"amount":118.327,"timestamp":1765573803858},"delay":0,"floatShares":21538900,"shares":24301089,"eps":-0.29473,"marketStatus":"Market Closed","change":-0.14,"latestTime":"12-12 16:00:00 EST","open":2.25,"high":2.26,"low":2.085,"amount":238808.7734,"amplitude":0.077778,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.29473,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":2.25,"preHourTrading":{"tag":"盘前","latestPrice":2.29,"preClose":2.25,"latestTime":"09:02 EST","volume":26,"amount":54.790000199999994,"timestamp":1765548161524},"postHourTrading":{"tag":"盘后","latestPrice":2.11,"preClose":2.11,"latestTime":"16:10 EST","volume":53,"amount":118.327,"timestamp":1765573803858},"volumeRatio":1.036506309205348,"impliedVol":0.6621,"impliedVolPercentile":0.198},"requestUrl":"/m/hq/s/ABVC/tweets","defaultTab":"tweets","newsList":[{"id":"2590953409","title":"Grant Cardone Says ADHD Isn't A Disorder But 'Misunderstood Genius' — It's A 'Gift From God' That Helps People Chase Multiple Passions","url":"https://stock-news.laohu8.com/highlight/detail?id=2590953409","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590953409?lang=en_us&edition=fundamental","pubTime":"2025-12-11 02:01","pubTimestamp":1765389660,"startTime":"0","endTime":"0","summary":"Grant Cardone isn't exactly known for keeping things subtle. The high-octane real estate mogul and motivational speaker has long made headlines with his unapologetically bold takes, and his views on mental health labels are no exception. This time, he's turning ADHD and bipolar disorder on their heads—insisting they're not disorders at all, but misdiagnosed brilliance.In November, Cardone posted a video to his official Facebook page with the caption: \"ADHD is just misunderstood genius.\". In the clip, Cardone appears on camera during an interview, explaining his belief that society pathologizes traits it doesn't understand. \"ADD, ADHD, bipolar—all these manic kind of people—they've been labeled something negative by some fake doctor,\" he said.To be clear, Cardone may wear many hats—investor, author, speaker—but none of them are \"doctor.\" He's not advising anyone to skip their meds or ignore real diagnoses. Many p","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/10/Grant-Cardone--Elena-Lyons-Cardone-At-Th.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/10/Grant-Cardone--Elena-Lyons-Cardone-At-Th.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/topics/25/12/49313663/grant-cardone-says-adhd-isnt-a-disorder-but-misunderstood-genius-its-a-gift-from-god-that-helps-people-chase-multiple-passions","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/topics/25/12/49313663/grant-cardone-says-adhd-isnt-a-disorder-but-misunderstood-genius-its-a-gift-from-god-that-helps-people-chase-multiple-passions","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["ADHD","ABVC","BK4139","BK4109","CCF"],"gpt_icon":0},{"id":"2590318095","title":"China Resources Double-Crane Pharmaceutical's ADHD Capsules Included in China's Insurance Catalog","url":"https://stock-news.laohu8.com/highlight/detail?id=2590318095","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590318095?lang=en_us&edition=fundamental","pubTime":"2025-12-09 15:29","pubTimestamp":1765265362,"startTime":"0","endTime":"0","summary":"Chinese authorities included the dextromethorphan hydrochloride sustained-release capsules manufactured by China Resources Double-Crane Pharmaceutical  subsidiary Henan Zhongshuai Pharmaceutical in the country's national insurance drug catalog.The drug is used as a psychostimulant for attention deficit hyperactivity disorder and nodular disorders in children aged 6 and above, according to a Tuesday filing with the Shanghai bourse.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ABVC","BK0175","BK0010","BK0239","BK0028","600062","BK0185","BK0188","ADHD"],"gpt_icon":0},{"id":"2586649185","title":"Tonix Pharma’s IND Clearance Boosts MDD Treatment Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2586649185","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586649185?lang=en_us&edition=fundamental","pubTime":"2025-11-25 01:06","pubTimestamp":1764003994,"startTime":"0","endTime":"0","summary":"Tonix Pharma ( ($TNXP) ) has shared an update. On November 24, 2025, Tonix Pharmaceuticals announced that the FDA cleared their IND application for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tonix-pharmas-ind-clearance-boosts-mdd-treatment-efforts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tonix-pharmas-ind-clearance-boosts-mdd-treatment-efforts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IND","BK4139","ABVC"],"gpt_icon":0},{"id":"2585012982","title":"When ADHD Meds Are Just the Start -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2585012982","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585012982?lang=en_us&edition=fundamental","pubTime":"2025-11-22 05:57","pubTimestamp":1763762220,"startTime":"0","endTime":"0","summary":"This is an edition of the WSJ Weekend Reads newsletter, a weekly look at our most colorful, thought-provoking and original feature stories on the business of life. If you're not subscribed, sign up here.Danielle Gansky was 7 years old when she started taking medication for ADHD. By her late 20s, she had taken 14 different kinds of psychiatric pills.Tens of thousands of kids who take prescription ADHD medication like Danielle did also wind up on other powerful psychotropic drugs. This week, we have an in-depth look at this trend of childhood overmedication and its lasting effects.\"I was living in a body hijacked by the medication,\" says Danielle, who at 29 still is struggling to wean herself off an antidepressant.Other topics that we delve into include trans-Atlantic cruises, the new \"Wicked\" movie and the joy of doing nothing in retirement.Enjoy your weekend with these and all the great reads below.Many children who are prescribed medication for ADHD end up taking other powerful psychi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADHD","BK4139","ABVC"],"gpt_icon":0},{"id":"2585141502","title":"For Kids, ADHD Pills Are Often Just the Start -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2585141502","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585141502?lang=en_us&edition=fundamental","pubTime":"2025-11-21 22:55","pubTimestamp":1763736900,"startTime":"0","endTime":"0","summary":"This is an edition of the WSJ Health newsletter, a weekly briefing on what's new in health, medicine, personal well-being and the business of healthcare. If you're not subscribed, sign up here.The newsletter won't publish the Friday after Thanksgiving. Your next edition will arrive the following week. Enjoy the break!For many kids, ADHD pills are the start of a drug cascade. The next steps are often powerful psychotropic drugs -- including antipsychotics, antidepressants and sleep aids -- even though their combined effects in young children haven't been studied closely.Separately, the founder of an ADHD startup was found guilty of conspiracy. Ruthia He, whose company Done Global was the subject of a WSJ investigation, was accused of orchestrating a scheme to profit from Adderall prescriptions.Trump administration officials discussed curbing the role of the FDA commissioner, Marty Makary, after complaints about his management style, though the idea was dropped.The FDA called for the rem","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139","ADHD"],"gpt_icon":0},{"id":"2584034809","title":"Millions of Kids Are on ADHD Pills. For Many, It's the Start of a Drug Cascade. -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2584034809","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584034809?lang=en_us&edition=fundamental","pubTime":"2025-11-20 10:00","pubTimestamp":1763604000,"startTime":"0","endTime":"0","summary":"By Shalini Ramachandran,Betsy McKay and Tom McGinty | Design by Audrey Valbuena. Danielle Gansky was 7 years old when an administrator at her upscale private girls' school in suburban Philadelphia flagged problems with her academic performance. She was a bubbly and creative kid, but she was easily distracted in class and her schoolwork was sloppy.More pills followed. Over the years, Gansky was always on two and sometimes three or more psychiatric drugs at once. By her late 20s, she had taken 14 different kinds of psychiatric pills.None of it ever felt right. The pills dulled her mind and made her irritable or sleepy. But when Gansky complained about the drugs, her doctors would up her dose or try another medication.\"I was living in a body hijacked by the medication,\" said Gansky, 29, who is still struggling to wean herself off an antidepressant. \"I didn't have the words or authority to challenge what I was being told.\". The Journal compared about 166,000 children aged 3 to 14 who start","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139","ADHD"],"gpt_icon":0},{"id":"2584929819","title":"Jury Convicts Done Global Founder In Adderall Distribution Scheme: WSJ Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2584929819","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584929819?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:26","pubTimestamp":1763569560,"startTime":"0","endTime":"0","summary":"A federal jury has convicted Ruthia He, the founder of the telehealth startup Done Global, for orchestrating a scheme that transformed the company into an unrestricted source for Adderall prescriptions. Prosecutors argued that this case highlighted serious abuses in online mental health care, as reported by the Wall Street Journal.Teva Pharmaceutical Industries Ltd  is the largest manufacturer of brand-name and generic Adderall, the most commonly usedto treat attention deficit hyperactivity disorder .In June 2024, Alphabet Inc.'s   Google and TikTok banned Done Global from advertising on their platforms amid a widening federal crackdown on the telehealth company's distribution of Adderall and other stimulants.Jurors concluded that He and Done's former top medical officer, David Brody, conspired to distribute controlled substances to more than 100,000 patients through lax prescribing practices that prioritized growth and revenue.One Done patient later died after receiving an Adderall pr","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/19/Middletown--Ct-Usa---August-7--2023-Adde.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/19/Middletown--Ct-Usa---August-7--2023-Adde.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/11/48954296/jury-convicts-done-global-founder-in-adderall-distribution-scheme-wsj-report","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/11/48954296/jury-convicts-done-global-founder-in-adderall-distribution-scheme-wsj-report","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["ADHD","LU0061474705.USD","LU1988902786.USD","LU1221951129.SGD","LU2089283258.USD","IE0004086264.USD","LU0882574139.USD","LU0494093205.USD","BK4561","IE00BJJMRX11.SGD","LU1803068979.SGD","IE0001KFT4U8.USD","IE00BFSS8Q28.SGD","LU1037948541.HKD","LU0203202063.USD","IE00BJTD4V19.USD","LU0957791311.USD","LU1815333072.USD","ABVC","LU0345768153.USD","LU1032955483.USD","SG9999014914.USD","LU2213496289.HKD","LU0320765489.SGD","IE00BMPRXN33.USD","LU0310800379.SGD","LU0312595415.SGD","LU0965508806.USD","IE0009356076.USD","LU0417517546.SGD","LU0648001328.SGD","LU0949170426.SGD","LU1196500208.SGD","LU0426417589.USD","LU1852331112.SGD","LU0079474960.USD","IE00BZ1G4Q59.USD","USJW.SI","LU0792757196.USD","TEVA","LU0456855351.SGD","LU1280957306.USD","LU2168564495.EUR","LU0820561818.USD","LU0949170772.SGD","LU2756315664.SGD","LU2463028550.USD","LU1037948897.HKD"],"gpt_icon":1},{"id":"2584964162","title":"ADHD Startup's Founder Is Found Guilty of Conspiracy in Adderall Case -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2584964162","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584964162?lang=en_us&edition=fundamental","pubTime":"2025-11-19 07:20","pubTimestamp":1763508000,"startTime":"0","endTime":"0","summary":"A jury found Ruthia He guilty of conspiring to distribute controlled substances after her startup Done Global became a ready source of Adderall prescriptions for more than 100,000 patients.The jury found He and Done's former top doctor, David Brody, guilty on two conspiracy counts and four counts of distributing controlled substances. He, Done's former chief executive, was also found guilty of conspiring to obstruct justice. Both defendants could go to prison for decades. Sentencing is scheduled for February.The company was the subject of a series of articles in The Wall Street Journal from 2022 to 2024 describing how some Done clinicians felt pressured to prescribe stimulants such as Adderall, while others wrote prescriptions much faster than is typical for clinicians doing thorough patient evaluations.The company has previously said it is a technology platform that connects patients with medical professionals and doesn't prescribe medications. It has also defended its prescription pr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","ADHD","BK4139"],"gpt_icon":0},{"id":"2583655005","title":"Cingulate Inc.’s Promising Market Position Bolstered by Strategic Partnerships and Innovative ADHD Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2583655005","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583655005?lang=en_us&edition=fundamental","pubTime":"2025-11-16 00:25","pubTimestamp":1763223929,"startTime":"0","endTime":"0","summary":"Cingulate Inc, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from Maxim Group reiterated a Bu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cingulate-inc-s-promising-market-position-bolstered-by-strategic-partnerships-and-innovative-adhd-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cingulate-inc-s-promising-market-position-bolstered-by-strategic-partnerships-and-innovative-adhd-treatment-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CING","BK4588","ABVC","XBI","BK4585","BK4139","XLV","BK4581","BK4007","ADHD","LABU"],"gpt_icon":0},{"id":"2583556739","title":"Press Release: Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2583556739","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583556739?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:21","pubTimestamp":1763036460,"startTime":"0","endTime":"0","summary":"- Closed registered direct offering for aggregate gross proceeds of US$175 million  led by a syndicate of prominent biopharmaceutical institutional investors -. - On track to report topline data from Phase 2 study evaluating CYB004 for the treatment of Generalized Anxiety Disorder  in Q1 2026 -. - Continues to advance Phase 3 studies of CYB003 for the adjunctive treatment of major depressive disorder  -. -The Company's cash position as at September 30, 2025 after giving effect to the net proceeds of the Registered Direct Offering is US$248 million -. - Repayment of outstanding convertible debentures to High Trail Special Situations LLC and debt retired in full -. - Company to host conference call and webcast at 8:00 a.m. ET today -. Patient rollovers continue into EXTEND, the long-term extension","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139","BK4604","BK4099","BK4022","BK4232","TM","BK4588","03160","BK4585","BK4555","R"],"gpt_icon":0},{"id":"2583561841","title":"BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21","url":"https://stock-news.laohu8.com/highlight/detail?id=2583561841","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583561841?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:00","pubTimestamp":1763031600,"startTime":"0","endTime":"0","summary":"Deep TMS becomes first and only TMS device cleared in treatment of patients aged 15 to 86 suffering from depressionBURLINGTON, Mass. and JERUSALEM, Israel, Nov.  13, 2025  (GLOBE NEWSWIRE) -- BrainsWa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/13/3187099/17676/en/BrainsWay-Receives-FDA-Clearance-of-Deep-TMS-as-Adjunct-Therapy-for-Major-Depressive-Disorder-MDD-in-Adolescents-Aged-15-to-21.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"gpt_icon":0},{"id":"2582033703","title":"TRICARE West Expands NeuroStar® TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2582033703","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582033703?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:33","pubTimestamp":1762961580,"startTime":"0","endTime":"0","summary":"New Policy Update Brings Innovative, Non-Drug Depression Treatment to Adolescents Across 26 StatesMALVERN, Pa., Nov.  12, 2025  (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technolo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/12/3186484/0/en/TRICARE-West-Expands-NeuroStar-TMS-Coverage-to-Include-Adolescents-Aged-15-Struggling-with-Depression.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STIM","BK4082","BK4139","ABVC"],"gpt_icon":0},{"id":"2582879286","title":"Press Release: Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879286","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879286?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779600,"startTime":"0","endTime":"0","summary":"Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate's transition toward commercialization pending FDA approval. Company also strengthens its cash position by completing a $6 million financing. Cingulate also announced it has completed a $6 million financing transaction, further strengthening its balance sheet and extending its cash runway into the second quarter of 2026, as the company prepares for commercialization, subject to FDA approval.\"Cingulate is at a pivotal moment as we prepare to bring CTx-1301 to market,\" said Bryan Downey, Chief Commercial Officer. \"The potential to deliver rapid onset and entire active-day ADHD symptom control in one daily dose is a substantial differentiator from medications currently available. With our new drug application now accepted for review, we're working closely with our partners at Indegene to establish the commercial infrastructure, market access execution, and launch readiness that will positi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADHD","03160","PSQ","BK4555","BK4585","QLD","MNQmain","SQQQ","TQQQ","BK4604","TM","QID","NVIW.SI","BK4007","USAW.SI",".IXIC","TSYW.SI","NQmain","BK4099","ABVC","USJW.SI","CING","BK4139","BK4588"],"gpt_icon":1},{"id":"2581026170","title":"Mind Medicine price target raised to $25 from $16 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2581026170","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581026170?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:55","pubTimestamp":1762516512,"startTime":"0","endTime":"0","summary":"Canaccord raised the firm’s price target on Mind Medicine (MNMD) to $25 from $16 and keeps a Buy rating on the shares. The firm added its MDD drug ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mind-medicine-price-target-raised-to-25-from-16-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mind-medicine-price-target-raised-to-25-from-16-at-canaccord-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","BK4139","BK4007","MNMD","BK4547"],"gpt_icon":0},{"id":"2581017131","title":"Press Release: MindMed Reports Q3 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2581017131","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581017131?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462860,"startTime":"0","endTime":"0","summary":"-- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet  in GAD: Voyage  and Panorama --. --Anticipated topline data readout from first Phase 3 study of MM120 ODT in MDD  accelerated to mid-2026, aligning with the anticipated initiation of second Phase 3 study in MDD --. --MM120 Phase 2b GAD Study published in the Journal of the American Medical Association --. --Continued advancement of pipeline with planned Phase 2a study initiation of MM402 in Autism Spectrum Disorder  in 4Q 2025--. --Cash, cash equivalents and marketable securities totaled $209.1 million as of September 30, 2025; completed underwritten public offering of common stock with net proceeds of $242.8 million on October 31, 2025--. --Conference call scheduled today at 4:30 p.m. EST--. placebo-controlled Phase 2b trial evaluating a single dose of MM120. across four dose levels in patients with moderate to severe GAD. The. Phase 2b study demonstrated a statistically si","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNMD","BK4007","BK4547","BK4232","ABVC","R","BK4139","BK4022","ODT"],"gpt_icon":0},{"id":"2581303013","title":"Yukiguni Maitake Sees FY Net Y2.01B","url":"https://stock-news.laohu8.com/highlight/detail?id=2581303013","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581303013?lang=en_us&edition=fundamental","pubTime":"2025-11-06 14:31","pubTimestamp":1762410660,"startTime":"0","endTime":"0","summary":"Yukiguni Maitake Co. Ltd. also released the following forecasts:. This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4139"],"gpt_icon":0},{"id":"2580192792","title":"ABVC BioPharma Q3 EPS $(0.05) Down From $(0.03) YoY, Sales $795.950K Up From $389.276K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2580192792","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580192792?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:16","pubTimestamp":1762179395,"startTime":"0","endTime":"0","summary":"ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.05) per share. This is a 66.67 percent decrease over losses of $(0.03) per share from the same period last year.  The company reported $795.950 thousand in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48589814/abvc-biopharma-q3-eps-0-05-down-from-0-03-yoy-sales-795-950k-up-from-389-276k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC"],"gpt_icon":0},{"id":"2580629072","title":"ABVC BioPharma Acquires Taiwan Land for $11 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2580629072","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580629072?lang=en_us&edition=fundamental","pubTime":"2025-11-03 20:31","pubTimestamp":1762173071,"startTime":"0","endTime":"0","summary":"ABVC BioPharma Inc. announced the completion of two land acquisitions in Taiwan totaling approximately USD 11 million during the third quarter of 2025. The investments include USD 7.67 million for the development of a plant factory for botanical raw materials and new drug substance research in Puli  by AiBtl BioPharma Inc., and USD 3.3 million for agricultural R&D and API cultivation in Longtan  by ABVC BioPharma, Inc. These strategic asset investments are expected to enhance the company's research and manufacturing capacity in Asia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL7mvvy9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"gpt_icon":0},{"id":"2580195416","title":"Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2580195416","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580195416?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:30","pubTimestamp":1761942600,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Oct.  31, 2025  (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/31/3178647/0/en/Neuronetics-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SQQQ",".IXIC","QID","NVIW.SI","QLD","USJW.SI","STIM","ABVC","MNQmain","TQQQ","TSYW.SI","NQmain","BK4082","BK4139","PSQ","USAW.SI"],"gpt_icon":1},{"id":"2579155141","title":"ABVC Biopharma Ties Executive Compensation to $1B Market Cap Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2579155141","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579155141?lang=en_us&edition=fundamental","pubTime":"2025-10-30 20:32","pubTimestamp":1761827550,"startTime":"0","endTime":"0","summary":"ABVC Biopharma Inc. has announced a new performance incentive plan for its directors and officers, which will take effect if the company reaches a $1 billion market capitalization for 30 consecutive trading days by December 31, 2027. Under the plan, eligible participants will receive shares equal to 1% of the company's outstanding common stock at the time of implementation, with the total value of awards capped at $10 million and individual grants capped at $1 million. The awards will be allocated based on specific milestones, with final approval required from the Board of Directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABVC Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electron","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL4rNSjX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abvcpharma.com","stockEarnings":[{"period":"1week","weight":-0.1245},{"period":"1month","weight":-0.2943},{"period":"3month","weight":-0.2596},{"period":"6month","weight":0.1921},{"period":"1year","weight":3.0971},{"period":"ytd","weight":2.5763}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.075359},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.015737},{"month":3,"riseRate":0.714286,"avgChangeRate":0.083622},{"month":4,"riseRate":0.285714,"avgChangeRate":0.004516},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.011992},{"month":6,"riseRate":0.285714,"avgChangeRate":1.316596},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.097297},{"month":8,"riseRate":0.5,"avgChangeRate":-0.054488},{"month":9,"riseRate":0.375,"avgChangeRate":-0.065685},{"month":10,"riseRate":0.375,"avgChangeRate":-0.067045},{"month":11,"riseRate":0.625,"avgChangeRate":0.051458},{"month":12,"riseRate":0.5,"avgChangeRate":-0.013118}],"exchange":"NASDAQ","name":"ABVC BioPharma, Inc.","nameEN":"ABVC BioPharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ABVC BioPharma, Inc.,ABVC,ABVC BioPharma, Inc.股票,ABVC BioPharma, Inc.股票老虎,ABVC BioPharma, Inc.股票老虎国际,ABVC BioPharma, Inc.行情,ABVC BioPharma, Inc.股票行情,ABVC BioPharma, Inc.股价,ABVC BioPharma, Inc.股市,ABVC BioPharma, Inc.股票价格,ABVC BioPharma, Inc.股票交易,ABVC BioPharma, Inc.股票购买,ABVC BioPharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction